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We identified the first two cases of the Finnish new var-
iant of Chlamydia trachomatis (F-nvCT) beyond Finland 
in two clinical urogenital specimens in Örebro County, 
Sweden. These Aptima Combo 2 assay-negative speci-
mens were Aptima  Chlamydia trachomatis  (CT) assay 
positive and had the characteristic C1515T mutation 
in the 23S rRNA gene. From 22 March to 31 May 2019, 
1.3% (2/158) of the CT-positive cases in Örebro County 
were missed because of the F-nvCT. International 
awareness, investigations and actions are essential.
Recently, false-negative  Chlamydia trachomatis  (CT) 
specimens in the nucleic acid amplification test (NAAT) 
Aptima Combo 2 (AC2) (Hologic Inc., San Diego, 
California, United States (US)) detecting CT (target: 23S 
rRNA) and  Neisseria gonorrhoeae  (target: 16S rRNA) 
were reported in Finland [1]. AC2 CT-negative/equivo-
cal specimens, mostly having relative light unit (RLU) 
signals of 20–85, were confirmed as CT positive using 
the Aptima  Chlamydia trachomatisassay (ACT) (target: 
16S rRNA) [1]. A C1515T mutation in the CT 23S rRNA 
gene was confirmed as the reason that the Finnish new 
variant of CT, F-nvCT, escapes detection in AC2 [2]. It 
is essential to timely investigate presence of F-nvCT 
internationally. Finland and Sweden have close rela-
tionships, including geographic proximity, and travel-
ling between the two countries is frequent.
We examined: (i) the proportion of consecutive clini-
cal AC2 CT-negative/equivocal specimens (RLUs 
20–99;  N. gonorrhoeae negative) from 1 January 2017 
to 31 May 2019; (ii) AC2 CT specimens (negative, 
equivocal and positive) and their RLUs from 1 May 
2018 to 31 May 2019; (iii) results from ACT testing of 
AC2 CT-negative/equivocal specimens (RLUs 20–99; N. 
gonorrhoeae  negative) from 22 March 2019 to 31 May 
2019 in Örebro County, Sweden; and (iv) partial 23S 
rRNA gene by sequencing (personal communication, 
K Hokynar, May 2019) in AC2 CT-negative/equivocal 
specimens that were ACT positive.
Chlamydia trachomatis diagnostics and 
incidence
In Örebro County (ca 300,000 inhabitants), Sweden, 
all CT and  N. gonorrhoeae  samples are analysed at 
the Örebro University Hospital using AC2 on a Panther 
instrument (Hologic Inc., San Diego, US). The incidence 
per 100,000 inhabitants of mandatorily reported CT 
cases in Örebro County has been similar to the national 
incidence and has decreased from 2013 (434/100,000 
population) to 2018 (334/100,000 population) (Figure 
1).
Initial investigations of possible Aptima 
Combo 2 false-negative Chlamydia 
trachomatis specimens
All consecutive clinical AC2 specimens obtained at 
Örebro University Hospital, Sweden from 1 January 
2017 to 31 May 2019 (n = 49,189, mainly vaginal swabs 
and urine specimens) were assessed.
Based on the initial data from Finland, nearly all 
false-negative AC2 CT specimens had RLUs of 20–85. 
Consequently, we decided to evaluate specimens with 
these AC2 RLUs in Örebro County, Sweden and addi-
tionally AC2 RLUs of 86–99 to cover all AC2 CT equivo-
cal specimens, i.e. RLUs 25–99. The proportion of AC2 
specimens with RLUs 20–99 was low from January 
2017 to September 2018, ranging between 0.07% and 
0.71%, but from October 2018 onwards, the proportion 
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was substantially higher (range: 1.26–2.94%) (Table 1). 
This prompted further investigations.
Of 19,083 AC2 results from 1 May 2018 to 31 May 2019, 
1,205 (6.3%) were reported as CT positive, 17,865 
(93.6%) as CT negative and 13 (0.07%) as CT equivo-
cal (RLU range for these specimens: 32–98). The RLUs 
of the AC2 CT and N. gonorrhoeae-negative specimens 
(n = 17,633) are shown in  Figure 2. Briefly, the mean 
RLU was 9.8, 75% of observations were RLUs ≤ 11, 90% 
were RLUs ≤ 14, 95% were RLUs ≤ 15 and 99% RLUs were 
≤ 21 (Figure 2).
Identification of possible cases of the 
Finnish new variant of Chlamydia 
trachomatis
Promptly after the first indication in March 2019 of pos-
sibly false-negative AC2 CT specimens, mostly having 
RLUs of 20–85, in Finland, confirmatory reflex testing 
using ACT of all specimens with AC2 RLUs 20–99 was 
implemented at Örebro University Hospital. Briefly, 
from 22 March to 31 May 2019, 156 specimens were AC2 
CT positive and 3,485 were CT negative. There were 77 
negative/equivocal specimens with RLUs 20–99 (RLUs 
20–24: n = 53, RLUs 25–30: n = 19, and RLUs 31–78: 
n = 5) and  N. gonorrhoeae-negative results. Seventy-
five (97.4%) of these specimens were interpreted as CT 
negative and two (2.6%) as CT equivocal by the Panther 
instrument. Seventy (90.9%) of the 77 specimens were 
available for ACT testing. One AC2 CT-equivocal speci-
men (RLU 78) and two AC2 CT-negative specimens 
(RLUs 30 and 32) were ACT positive (RLUs 4,318–7,168). 
However, the AC2 CT-equivocal specimen was also pos-
itive in repeated AC2 testing (RLU 729).
Figure 1
Incidence of mandatorily reported Chlamydia trachomatis infection in Örebro County, Sweden and national Swedish 
incidence, 1997–2018
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An increased incidence was seen in 2007 because of the introduction of new nucleic acid amplification tests (NAATs) that also detected the 
Swedish new variant of Chlamydia trachomatis (nvCT). It was a ‘catch up’ of samples missed because of the Swedish nvCT.
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Confirmed cases of the Finnish new variant 
of Chlamydia trachomatis
Both the two repeatedly AC2 CT-negative/ACT-positive 
specimens contained the CT 23S rRNA C1515T muta-
tion, which was recently confirmed as the cause of 
the false-negative/equivocal AC2 CT results of F-nvCT 
specimens [2]. These two Swedish F-nvCT specimens 
were sampled in May 2019 from one Swedish male and 
one Swedish female in their early 20s. Both patients 
received CT-positive results based on the ACT testing, 
and recommended treatment [3]. The female had one 
unknown sexual contact in Norway. The male named 
several female sexual contacts in Sweden, one of 
whom was from Finland who however tested negative 
for CT in late May 2019.
Discussion
We identified the first two cases of F-nvCT beyond 
Finland, in two clinical specimens in Örebro County, 
Sweden. Correspondingly, from 22 March to 31 May 
2019, 1.3% (2/158) of the CT-positive cases in Örebro 
County were missed because of the F-nvCT. Further 
investigations are ongoing in Örebro County and in the 
two additional Swedish laboratories using AC2. One of 
these laboratories examined more than 110,000 AC2 
specimens in 2018, and the proportion of specimens 
with AC2 RLUs of 20–99 has been stably low since 2016 
(0.15–0.16%). Detailed examination has now been initi-
ated in this laboratory as well. Based on the close rela-
tionships between Finland and Sweden, it is likely that 
additional F-nvCT cases will be detected in Sweden. 
It is highly important to perform a timely F-nvCT sur-
veillance study in the Swedish capital city, Stockholm. 
Stockholm is geographically close to Finland and trav-
elling between Stockholm and many Finnish cities with 
airplanes and ferries is frequent.
It is essential to detail the national proportion and 
geographic distribution of cases of F-nvCT in Finland 
and Sweden, and possible presence in additional coun-
tries. Hologic, the manufacturer of the AC2, is devel-
oping an Aptima-format research assay containing an 
F-nvCT detection probe for surveillance, particularly 
in European settings where elevated levels of AC2 CT 
false-negative/equivocal results have been verified [2]. 
When such an assay is developed and validated, a well-
designed, pan-European, manufacturer-independent 
F-nvCT surveillance study would be valuable. Notably, 
only the CT probe detection in AC2, and not the AC2 
target capture or transcription-mediated amplification, 
is affected by the F-nvCT. Furthermore, other com-
mercially-available US Food and Drug Administration-
approved CT NAATs detect the F-nvCT.
At current date, European laboratories using AC2 
should retrospectively and prospectively review their 
CT results, the proportions of negative, equivocal, and 
positive specimens, and the RLUs of all negative/equiv-
ocal specimens, and examine unexplained changes in 
the CT epidemiology or positivity rate. In European set-
tings, until a revised version of AC2 that detects also 
F-nvCT is available, specimens with AC2 RLUs 15–99, 
CT-negative specimens that are N. gonorrhoeae equiv-
ocal/positive and CT-equivocal specimens independent 
on N. gonorrhoeae results should be reflex tested with 
ACT [2,4]. This will identify possible cases of F-nvCT 
specimens. To identify confirmed cases of F-nvCT spec-
imens, CT 23S rRNA gene sequencing of specimens 
that are AC2 CT negative/equivocal and ACT positive is 
essential until other mutant-specific assays are avail-
able. Where false-negative AC2 CT tests have been 
reported to patients, patient recall policies need to 
be implemented. The look-back period will depend on 
the local epidemiology of F-nvCT, taking spontaneous 
Table 
Number and proportion of Aptima Combo 2 Chlamydia trachomatis (CT)-negative/equivocal specimens with relative light 
unit signals of 20–99 of all Aptima Combo 2 CT-negative specimens, Örebro County, Sweden, January 2017–May 2019
Month
2017 2018 2019
n/N % n/N % n/N %
January 3/1,672 0.18 2/1,793 0.11 47/1,947 2.41
February 4/1,682 0.24 6/1,572 0.38 18/1,434 1.26
March 6/1,815 0.33 6/1,575 0.38 22/1,598 1.38
April 8/1,496 0.53 7/1,652 0.42 33/1,316 2.51
May 5/1,581 0.32 1/1,516 0.07 34/1,599 2.13
June 11/1,554 0.71 3/1,222 0.25 NA NA
July 6/1,356 0.44 5/1,482 0.34 NA NA
August 4/1,772 0.23 5/1,722 0.29 NA NA
September 3/1,726 0.17 6/1,727 0.35 NA NA
October 4/1,726 0.23 23/1,741 1.32 NA NA
November 9/1,775 0.51 29/1,513 1.92 NA NA
December 9/1,403 0.64 39/1,328 2.94 NA NA
NA: not applicable.
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clearance of CT infection, social consequences and 
potential risk of reinfection into account.
In due course, many scientific issues should be eluci-
dated, such as where and when and how the F-nvCT 
emerged and is spreading, how it is evolving and 
the fitness of F-nvCT nationally and internationally. 
Moreover, it should be studied if the F-nvCT is asso-
ciated with increases in CT-associated complications/
sequelae, symptomatic/asymptomatic infection and 
spread in different subpopulations. Whole genome 
sequencing of F-nvCT from Aptima specimens is in pro-
gress to address several scientific issues. A mutant-
specific, real-time PCR is also under development. 
Notably, the CT 23S rRNA C1515T mutation in F-nvCT 
has not been found in previously published CT genome 
sequences [5] and is most likely not associated with 
any resistance to first- or second-line therapy with 
azithromycin [3].
In general, for CT infections and other infections, it is 
imperative to closely monitor and analyse incidence, 
locally, nationally and internationally. It is also impor-
tant to alert and further examine unexplained notable 
decreases or increases in diagnosis rates in a timely 
manner. Furthermore, regular and more comprehen-
sive evaluations of different diagnostic methods are 
crucial for maintaining diagnostic quality. The samples 
included in such evaluations should reflect not only 
currently circulating strains, but also temporally, geo-
graphically and genetically diverse strains. Frequent 
participation is also crucial in appropriate external 
quality assessments schemes, which should ideally 
include similar diverse strains, different diagnostic 
methods and divergent populations. Based on the 
Figure 2
Relative light units of Chlamydia trachomatis and Neisseria gonorrhoeae-negative Aptima Combo 2 specimens, Örebro 
County, Sweden, May 2018–May 2019 (n = 17,633)
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RLUs: relative light units.
The black line (RLU ≥ 15) shows the currently recommended cut-off for confirmatory reflex testing using the Aptima Chlamydia trachomatis 
assay [2].
The mean RLU was 9.8, while the median was 9 and the range 3–50. Furthermore, 75% of observations were RLUs ≤ 11; 90% were ≤ 14; 95% 
were ≤ 15; 96% were ≤ 16; 97% were ≤ 17; 98% were ≤ 18; and 99% were ≤ 21.
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identification of the Swedish nvCT in 2006 [6-9],  N. 
gonorrhoeae porA pseudogene mutants [10,11] and the 
F-nvCT [1,2], diagnostic test escape mutants of CT and 
other infectious agents may be more common than real-
ised and inevitable consequences of the frequent use 
of NAATs and the ongoing evolution of the microorgan-
isms. Accordingly, two targets might need to be consid-
ered in all diagnostic NAATs [7,9,10]. International and 
national surveillance programmes capturing diagnostic 
test escape mutants, and cross-reacting microorgan-
isms, for CT and other pathogens should also be con-
sidered, particularly for diagnostic NAATs with a single 
target. Finally, preservation and/or confirmatory test-
ing of 1–5% of representative negative/equivocal NAAT 
specimens each year would be valuable.
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